Brief: Cereno Scientific Signs Agreement With Fluidda
30/09/2024 07:17
Sept 30 (Reuters) - Cereno Scientific AB CRNOSb.ST :
* SIGNS AGREEMENT WITH FLUIDDA, TO EVALUATE THE IMPACT OF
ITS HDAC
INHIBITOR CS1 ON REVERSE REMODELING OF PULMONARY VESSELS IN
PATIENTS WITH PAH
Source text for Eikon: ID:nWkr12yWxg
Further company coverage: CRNOSb.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Cereno Scientific AB
See all newsBrief: Cereno Scientific Carries Out Directed Share Issue Of SEK 60 Mln
Brief: Cereno Scientific Strengthens Patent Protection For Cs1 In Canada
Sweden's Cereno Scientific Q1 net loss widens amid clinical development
Brief: Cereno Scientific Q1 Loss After Financial Items SEK 28.6 Mln
Brief: Cereno Enters Collaboration With PHA Europe & Global